RNA-seq analysis of human glioma LN229 cells treated with 17-hydroxyjolkinolide B

ABSTRACT: Glioma is a highly aggressive brain tumor for which effective therapeutic options remain limited. Although natural products represent an important source of anticancer agents, the anti-glioma activity of 17-hydroxyjolkinolide B (HJKB), a diterpenoid derived from Euphorbia fischeriana, remains poorly understood. Here, screening of 280 natural compounds identified HJKB as an active inhibitor of glioma cell growth. HJKB suppressed the proliferation, migration, and invasion of LN229 and U87 cells, induced G1-phase cell-cycle arrest, and inhibited LN229 xenograft growth in vivo. Transcriptomic profiling identified 5321 differentially expressed genes, with prominent enrichment in chromosome segregation, DNA replication, and cell-cycle checkpoint processes. Integration of transcriptomic and network pharmacology results identified 36 overlapping targets and prioritized CASP3, CDK2, MDM2, and EGFR as candidate molecules. Molecular docking suggested potential interactions between HJKB and these proteins. LiP-SMap further revealed altered local proteolytic accessibility of an EGFR-derived peptide within extracellular domain I, nominating EGFR as a candidate HJKB-responsive protein. HJKB treatment was also accompanied by transcriptional changes in several candidate genes. Collectively, these findings establish the in vitro and in vivo anti-glioma activity of HJKB and associate its pharmacological effects with cell-cycle dysregulation, while supporting further investigation of EGFR as a candidate HJKB-responsive protein.

ORGANISM(S): Homo sapiens

PROVIDER: GSE344508 | GEO | 2026/08/25

REPOSITORIES: GEO